-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2019, pharmaceutical industry companies have generally faced problems such as weak revenue growth, patent expiration, and rising cost of new drug research and development, which has also forced large pharmaceutical companies to speed up innovation and transformation and develop new results; or open up through outsourcing The "snake swallowing elephant" model continuously enriches the product pipeline and maintains stable profit growth
.
Judging from the mergers and acquisitions of pharmaceutical giants in recent years, there are not many cases of mergers and acquisitions with tens of billions of dollars.
For example, Takeda Pharmaceutical announced the acquisition of the British pharmaceutical company Shire for $62 billion; Gene; due to the imminent expiry of the blockbuster product "Humei Le", AbbVie spent US$64.
1 billion to acquire the medical beauty giant Allergan; Merck acquired Accleron Pharmaceuticals for US$11.
5 billion to strengthen the cardiovascular pipeline.
Acquired Schering-Plough for $41.
1 billion and acquired K medicine under the latter company
.
So, how are these pharmaceutical companies that once spent tens of billions of dollars "snake swallowing elephants" developing now? Are they moving towards their ideal goals? From the current situation, among the above-mentioned pharmaceutical giants with huge acquisitions, Takeda Pharmaceutical has performed particularly well
.
It is understood that after the acquisition of Shire, Takeda Pharmaceutical has done two things, one is to expand the product pipeline to improve the overall competitiveness; the other is to save a lot of expenses through internal integration in management, R&D and production/supply, and at the same time The company's core business profit margin also improved significantly
.
Statistics show that in the past three years, Takeda Pharmaceutical's assets have soared from 4 trillion yen to about 14 trillion yen, more than tripled; revenue has also increased from 2 trillion yen to over 30,000 yen.
100 million yen, more than 1.
5 times
.
In addition, the number of its subsidiaries and employees have also doubled
.
And the experience of several other pharmaceutical giants seems to be ups and downs
.
For example, take Bristol-Myers Squibb, which acquired Celgene for a huge amount, as an example.
After its acquisition of Xinjian, it occupied the global market seat of three blockbuster products, including the anticoagulant drug apixaban, lenalidomide and O drug
.
However, due to the competition from competing K drugs, the sales revenue of O drug is weak, and O drug has faced many challenges in the development of indications, and it has not been able to enter the medical insurance catalogue in the medical insurance negotiation.
It has to turn to increasing charitable donations.
Drug (PAP) efforts in exchange for the market
.
Bristol-Myers Squibb’s revenue has increased from $26.
145 billion in 2019 to $42.
518 billion in 2020.
After entering 2021, revenue growth has been sluggish.
The company expects global revenue to grow by high single digits in 2021
.
Bristol-Myers Squibb executives once described the focus of the company's development in 2021 in three words: collaboration, adaptation and development
.
Recently, Bristol-Myers Squibb expects revenue of about $47 billion in 2022
.
Adjusted EPS of $7.
65 to $7.
95 is expected in 2022
.
After AbbVie acquired the medical beauty giant Allergan, its medical beauty business also experienced a difficult year due to the impact of the epidemic
.
Botox, for example, declined 43% from the second quarter of 2019 to the same period in 2020
.
But under AbbVie's management, the anti-wrinkle formula is expected to bring in nearly $3.
8 billion in revenue for Allergan
.
Entering 2021, its beauty product revenue is also growing rapidly.
In the second quarter of 2021, the global beauty product net revenue was 1.
434 billion US dollars, an increase of over 100%.
Other products such as immunology products, hematology and oncology products also increased.
The overall performance Strong performance
.
.
Judging from the mergers and acquisitions of pharmaceutical giants in recent years, there are not many cases of mergers and acquisitions with tens of billions of dollars.
For example, Takeda Pharmaceutical announced the acquisition of the British pharmaceutical company Shire for $62 billion; Gene; due to the imminent expiry of the blockbuster product "Humei Le", AbbVie spent US$64.
1 billion to acquire the medical beauty giant Allergan; Merck acquired Accleron Pharmaceuticals for US$11.
5 billion to strengthen the cardiovascular pipeline.
Acquired Schering-Plough for $41.
1 billion and acquired K medicine under the latter company
.
So, how are these pharmaceutical companies that once spent tens of billions of dollars "snake swallowing elephants" developing now? Are they moving towards their ideal goals? From the current situation, among the above-mentioned pharmaceutical giants with huge acquisitions, Takeda Pharmaceutical has performed particularly well
.
It is understood that after the acquisition of Shire, Takeda Pharmaceutical has done two things, one is to expand the product pipeline to improve the overall competitiveness; the other is to save a lot of expenses through internal integration in management, R&D and production/supply, and at the same time The company's core business profit margin also improved significantly
.
Statistics show that in the past three years, Takeda Pharmaceutical's assets have soared from 4 trillion yen to about 14 trillion yen, more than tripled; revenue has also increased from 2 trillion yen to over 30,000 yen.
100 million yen, more than 1.
5 times
.
In addition, the number of its subsidiaries and employees have also doubled
.
And the experience of several other pharmaceutical giants seems to be ups and downs
.
For example, take Bristol-Myers Squibb, which acquired Celgene for a huge amount, as an example.
After its acquisition of Xinjian, it occupied the global market seat of three blockbuster products, including the anticoagulant drug apixaban, lenalidomide and O drug
.
However, due to the competition from competing K drugs, the sales revenue of O drug is weak, and O drug has faced many challenges in the development of indications, and it has not been able to enter the medical insurance catalogue in the medical insurance negotiation.
It has to turn to increasing charitable donations.
Drug (PAP) efforts in exchange for the market
.
Bristol-Myers Squibb’s revenue has increased from $26.
145 billion in 2019 to $42.
518 billion in 2020.
After entering 2021, revenue growth has been sluggish.
The company expects global revenue to grow by high single digits in 2021
.
Bristol-Myers Squibb executives once described the focus of the company's development in 2021 in three words: collaboration, adaptation and development
.
Recently, Bristol-Myers Squibb expects revenue of about $47 billion in 2022
.
Adjusted EPS of $7.
65 to $7.
95 is expected in 2022
.
After AbbVie acquired the medical beauty giant Allergan, its medical beauty business also experienced a difficult year due to the impact of the epidemic
.
Botox, for example, declined 43% from the second quarter of 2019 to the same period in 2020
.
But under AbbVie's management, the anti-wrinkle formula is expected to bring in nearly $3.
8 billion in revenue for Allergan
.
Entering 2021, its beauty product revenue is also growing rapidly.
In the second quarter of 2021, the global beauty product net revenue was 1.
434 billion US dollars, an increase of over 100%.
Other products such as immunology products, hematology and oncology products also increased.
The overall performance Strong performance
.
